The Institute

About us

With 123 years of history, Butantan works to prevent diseases like Covid-19, flu, tetanus, diphtheria, hepatitis A and B, chikungunya, whooping cough, dengue, HPV and rabies. In 2023, Butantan produced:

  • 90 million doses of flu vaccine
  • 31 million doses of vaccines against hepatitis A and B, HPV, DTaP and rabies
  • 13 million doses of Covid-19 vaccine
  • 600 thousand units of serum against venoms, bacterial toxins and the rabies virus
  • 380 thousand units of the monoclonal antibody Adalimumab

Instituto Butantan is the main producer of immunobiologicals in Brazil. It is responsible for a considerable percentage of the national production of hyperimmune sera and vaccine antigens, which make up the vaccines used in the National Immunization Program (Programa Nacional de Imunizações, PNI) of the Brazilian Ministry of Health. Our technological development activities in the production of health inputs are associated with the production of vaccines, antitoxins and antivenoms, and biopharmaceuticals for human use.

We export sera and vaccines for over 10 countries in Latin America and Europe.

Our course of action

Official documents

Decree no. 878-A, of February 23, 1901- Law providing for the Instituto Serumtherapico, predecessor of Instituto Butantan.

Decree no. 64,518, of October 10, 2019- Law providing for the reorganization of Instituto Butantan.